Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05195775 · ClinicalTrials.gov registry record · Phase 2
Tadalafil as Adjuvant Therapy for DMD
A Phase 2 study of Duchenne Muscular Dystrophy, sponsored by University of Florida.
- Active
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT05195775: Active Phase 2 study of Duchenne Muscular Dystrophy, sponsored by University of Florida.
NCT05195775 is a Phase 2 study of Duchenne Muscular Dystrophy that is active but no longer recruiting, run by University of Florida. The registered enrollment target is 25 participants, below the 412-participant average among 48 other Duchenne Muscular Dystrophy trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05195775, a Phase 2 study of Duchenne Muscular Dystrophy, is active but no longer recruiting, sponsored by University of Florida.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
This project will assess the vascular responsiveness in leg muscles of boys with Duchenne muscular dystrophy (DMD) to one single dose of tadalafil, a common vasodilator drug, using non-invasive techniques (MRI or Doppler ultrasound) and exercise testing. These findings will provide proof of concept for a subsequent intervention study to demonstrate efficacy of longer-term tadalafil to counter sympathetic vasoconstriction and slow disease progression in DMD. It will also inform whether a group of patients do not respond to the drug.
Primary Outcome
MRI technique to measure microvascular function in skeletal muscle
Conditions Studied
Interventions
- DRUG Tadalafil
Study Locations (1)
Florida
- University of Florida - Gainesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2021-12-14 |
| Est. Completion | 2025-09-05 |
| Phase | Phase 2 |
What the registry record for NCT05195775 still lists
NCT05195775 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 412-participant average among 48 other Duchenne Muscular Dystrophy trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Duchenne Muscular Dystrophy appearing as the primary indexed condition, and to 1 intervention - of which Tadalafil is the first listed.
NCT05195775 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT05195775 about?
NCT05195775 is a clinical study titled "Tadalafil as Adjuvant Therapy for DMD". This project will assess the vascular responsiveness in leg muscles of boys with Duchenne muscular dystrophy (DMD) to one single dose of tadalafil, a common vasodilator drug, using non-invasive techniques (MRI or Doppler ultrasound) and exercise testing. These findings will provide proof of concept ...
What is the current status of trial NCT05195775?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2021-12-14. Estimated completion is 2025-09-05.
What conditions does trial NCT05195775 study?
This clinical trial studies the following conditions: Duchenne Muscular Dystrophy.
What interventions are being tested in trial NCT05195775?
The interventions under investigation include: Tadalafil (DRUG).
Who is sponsoring clinical trial NCT05195775?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05195775 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Duchenne Muscular Dystrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05195775's enrollment target sits among peer trials
25 35th of 48 higher than 14 of 48 other Duchenne Muscular Dystrophy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Duchenne Muscular Dystrophy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)
RECRUITING · Phase 2
-
Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients
RECRUITING · Phase 2
-
Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study
RECRUITING · Phase 2
-
NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)
RECRUITING · Phase 2
-
Vasodilator and Exercise Study for DMD (VASO-REx)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI